Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Arbormentis/Relmada Therapeutics

Next Previous
Drug Profile

Psilocybin - Arbormentis/Relmada Therapeutics

Alternative Names: REL-P11

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arbormentis; Institute for Research in Biomedicine; University of Padua
  • Developer Arbormentis; Relmada Therapeutics
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Metabolic disorders
  • Research Psychiatric disorders
  • No development reported Neurodegenerative disorders

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in Neurodegenerative-disorders in Unknown
  • 14 Nov 2024 Phase-I clinical trials in Metabolic disorders in Canada (unspecified route)
  • 19 Mar 2024 Relmada Therapeutics plans a phase I trial for metabolic disorder in Canada, by year end 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top